MedWatch

Hansa Biopharma receives positive opinion for transplant asset in EU: "Amazing"

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends conditional approval of Hansa Biopharma's main asset Idefirix in EU. The Swedish biotech firm expects to launch the drug by approximately fourth quarter of 2020.

Photo: Hansa Biopharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles